Keyphrases
Duvelisib
100%
Randomized Placebo-controlled Trial
100%
Critically Ill Patients
100%
Investigator-initiated
100%
COVID-19
100%
Overall Survival
71%
Placebo
57%
Confidence Interval
42%
Adverse Events
28%
Viral Load
28%
Severe Coronavirus Disease 2019
28%
Inflammatory Cytokines
14%
Hazard Ratio
14%
High Mortality
14%
Critically Ill
14%
Cardiac Disease
14%
Corticosteroids
14%
Flow Cytometric Analysis
14%
Shock
14%
Intensive Care Unit Length of Stay
14%
Safety Endpoints
14%
Cell-mediated
14%
Primary Diagnosis
14%
Hospital Care
14%
Critical Illness
14%
Load Estimation
14%
Dose Adjustment
14%
Measurement Analysis
14%
Lung Inflammation
14%
Phosphatidylinositol 3-kinase Inhibitor
14%
Acute Respiratory Distress Syndrome
14%
Cytokine Measurement
14%
Acute Hypoxemic Respiratory Failure
14%
Viral Kinetics
14%
Phosphoinositide 3-kinase Pathway
14%
Critical Care Trials
14%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Duvelisib
100%
Coronavirinae
100%
Diseases
100%
Overall Survival
71%
Cytokine
57%
Adverse Event
28%
Respiratory Failure
14%
Phosphatidylinositol 3 Kinase
14%
Heart Disease
14%
Adult Respiratory Distress Syndrome
14%
Critical Illness
14%
Phosphatidylinositol 3 Kinase Inhibitor
14%
Medicine and Dentistry
Duvelisib
100%
Placebo
100%
COVID-19
100%
Overall Survival
71%
Cytokine
42%
Adverse Event
28%
Inflammatory Cytokine
14%
Phosphoinositide 3-Kinase
14%
Hazard Ratio
14%
Intensive Care
14%
Heart Disease
14%
Intensive Care Unit
14%
Respiratory Failure
14%
Acute Respiratory Distress Syndrome
14%
Critical Illness
14%
Phosphoinositide 3-Kinase Inhibitor
14%